中图分类号:
陈芳, 张弛, 崔敏. 利奈唑胺注射液致重度血小板减少1例[J]. 中国药物警戒, 2017, 14(4): 254-254.
| [1] Noskin G A, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci[J]. Antimicrob Agents Chemother, 1999, 43(8): 2059-2062. [2] Ozkaya-Parlakay A, Kara A, Celik M, et al. Early lactic acidosis associated with linezolid therapy in paediatric patients[J]. Int J Antimicrob Agents, 2014, 44(4): 334-336. [3] Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy[J]. Clin Infect Dis, 2002, 34(5): 695-698. [4] Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia[J]. Int J Antimicrob Agents. 2009, 33(1): 98-99. [5] Gerson S L, Kaplan S L, Bruss J B, et al. Hematologic effects of linezolid: summary of clinical experience[J]. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726. [6] Antal E J, Hendershot P E, Batts D H, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine[J]. J Clin Pharmacol, 2001, 41(5): 552-562. [7] Lin Y H, Wu V C, Tsai I J, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency[J]. Int J Antimicrob Agents, 2006, 28(4): 345-351. [8] Wu V C, Wang Y T, Wang C Y, et al. High frequency of thrombocytopenia and anemia among patients with end-stage renal disease[J]. Clin Infect Dis, 2006, 42(1):66-72 [9] 董海燕, 邹雅敏, 董亚琳, 等. Logistic模型和ROC曲线对利奈唑胺致血小板减少症的预测分析[J]. 中国医院药学杂志, 2013(22): 1827-1831. [10] Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse eveents induced by linezolid[J]. Antimicrob Afents Chemother, 2007, 51(7):2559-2663. [11] Matsumoto K, Takeshita A, Ikawak, et al. Higer linezolid exposure and higher frequency of thrombocytopeniain patients with renal dysfunction[J]. Int J Antimicrob Agents, 2010, 36(2):179-181. [12] Grau S, Morales-Molina J A, Mateude Antonio J, et al. Linezolid:low pretreatment platelet values could increase the risk of thrombocytopenia[J]. J Antimicro Chemother, 2005 56(2):440-1. [13] Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of Linezolid Clearance on the Induction of Thromobocytopenia and Reduction of Hemoglobin[J]. Am J Med Sci, 2011, 342(6):456-460. [14] Niwa T, Suzuki A, Sakakibara S, et al. Reftrospective cohort chart review study of fafctorsassociated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy[J]. Cli Ther, 2009, 31(10):2126-2133. [15] Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients[J]. Antimicrob Agents Chemother, 2011,55(5):1867-186173. |
| [1] | 李欣颖, 包蕾, 李舒冉, 赵荣华, 孙静, 谢丹, 鲍岩岩, 郭姗姗, 崔晓兰, 耿子涵. 疏风解毒胶囊对甲型流感病毒H1N1特异性抗体的影响[J]. 中国药物警戒, 2025, 22(8): 841-850. |
| [2] | 王馨蔚, 彭一峰, 孙静, 冀祖恩, 包蕾, 罗恒磊, 耿子涵, 张虎娟, 李舒冉, 张敬升, 郭姗姗, 崔晓兰, 赵荣华. 一叶抗流感胶囊对人冠状病毒229E感染致小鼠肺炎的影响[J]. 中国药物警戒, 2025, 22(8): 851-855. |
| [3] | 谢锐, 孙绮悦, 李艳英, 张敬升, 赵荣华, 郭姗姗, 耿子涵, 包蕾, 高双荣, 崔晓兰, 谢丹, 孙静. 双参苓颗粒对镉中毒致小鼠慢性肾功能衰竭模型的影响[J]. 中国药物警戒, 2025, 22(8): 856-862. |
| [4] | 陈思颖, 丁雪丽, 刘淑佳, 张晓朦, 张冰, 林志健. 中草药心脏毒性预测模型研究[J]. 中国药物警戒, 2025, 22(8): 869-875. |
| [5] | 蔡海丽, 张晓朦, 刘亚迪, 陈莉娟, 王雨, 张冰. 基于铁死亡探讨中药防治蒽环类药物心脏毒性的机制[J]. 中国药物警戒, 2025, 22(8): 876-882. |
| [6] | 郑海云, 王志钢, 吴宏伟, 王少南, 王斌. 基于UPLC-Q-Exactive Orbitrap HRMS的补心安眠汤体内外化学成分分析[J]. 中国药物警戒, 2025, 22(8): 883-888. |
| [7] | 孙雅, 王旭, 孙志, 周玉冰. 脓毒症伴急性肾损伤重症患者利奈唑胺剂量分析[J]. 中国药物警戒, 2025, 22(8): 889-895. |
| [8] | 史琪, 王建新, 王桂杰, 陆悦阳, 主佳旭, 高蕊. 清气化痰丸治疗慢性阻塞性肺疾病急性加重的系统评价[J]. 中国药物警戒, 2025, 22(8): 914-919. |
| [9] | 应婕, 徐霄龙, 李博, 刘腾文, 刘清泉. 金花清感颗粒治疗轻型流感临床应用的Meta分析[J]. 中国药物警戒, 2025, 22(8): 920-923. |
| [10] | 柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927. |
| [11] | 梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932. |
| [12] | 刘疆, 陈洁, 邱思鸿, 李娜, 周莹, 陈永刚, 罗季. 基于美国FAERS数据库的奥马环素和莫西沙星不良事件分析[J]. 中国药物警戒, 2025, 22(8): 933-936. |
| [13] | 赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940. |
| [14] | 周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943. |
| [15] | 陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
